Progesterone Global Market Report 2025

The progesterone market size has grown rapidly in recent years. It will grow from $1.56 billion in 2024 to $1.79 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. Factors contributing to this historic growth include a surge in infertility cases, increasing reliance on assisted reproductive technologies, a rise in menstrual disorders, heightened awareness of women’s health, and growing demand for bioidentical hormone treatments.

The progesterone market size is expected to see rapid growth in the next few years. It will grow to $3.09 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. This projected growth is driven by a rising population of aging women, higher rates of hormonal imbalance conditions, increased preference for injectable and transdermal drug delivery options, greater emphasis on preventive health measures, and expanding healthcare expenditures. Key trends expected during the forecast period include innovations in transdermal drug delivery, creation of long-acting formulations, progress in the customization of bioidentical hormones, enhanced oral absorption methods, and the development of intelligent drug delivery patch systems.

The growing prevalence of hormonal disorders is anticipated to drive the expansion of the progesterone market in the coming years. Hormonal disorders are medical conditions that result from imbalances or malfunctions within the endocrine system, which is responsible for producing and regulating hormones that influence essential bodily functions such as metabolism, reproduction, growth, and mood. The rise in hormonal disorders can be attributed to modern lifestyle factors, including unhealthy diets, chronic stress, physical inactivity, and increased exposure to environmental toxins. Progesterone plays a key role in managing these disorders by helping to restore hormonal balance, regulate menstrual cycles, and alleviate symptoms associated with estrogen dominance. Additionally, it supports the function of other hormones like estrogen and cortisol, thereby contributing to the stabilization of the endocrine system and addressing conditions such as polycystic ovary syndrome (PCOS) and premenstrual syndrome (PMS). For example, in January 2025, the World Health Organization reported that PCOS is a significant public health concern and one of the most common hormonal disorders among women of reproductive age, affecting an estimated 6-13% annually. As a result, the increasing incidence of hormonal disorders is fueling the growth of the progesterone market.

Key players in the progesterone market are investing in innovative drug formulations, such as soft vaginal capsules, to enhance patient compliance and improve drug absorption. Soft vaginal capsules are smooth, gel-like inserts intended for vaginal administration, enabling localized drug delivery to address infections, promote hormonal balance, and support overall vaginal health. In April 2024, Besins Healthcare (UK) Limited, a pharmaceutical manufacturing company based in the UK, introduced Prometrium 400mg soft vaginal capsules aimed at preventing miscarriage in women experiencing early pregnancy bleeding and with a history of recurrent miscarriage. This novel product, the first of its kind licensed in the UK, offers a non-invasive and targeted delivery method that enhances progesterone absorption at the site of action, leading to improved therapeutic outcomes and greater patient adherence.

In October 2024, Audax Private Equity, a US-based investment firm, acquired the clinical services division of Avantor, Inc. for an undisclosed sum. With this acquisition, Audax launched Resonant Clinical Solutions, an independent platform within the outsourced clinical trial services industry. The move is intended to expand service offerings and capitalize on long-standing relationships with clients. Avantor, Inc., the former owner of the division, is a biotechnology company based in the US that supplies progesterone.

Major players in the progesterone market are Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Allergan plc, AbbVie Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd, Gedeon Richter Plc., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Cadila Pharmaceuticals Ltd., Aspen Pharmacare, BIOCON Ltd., Zhejiang Xianju Pharmaceutical Co. Ltd., Beximco Pharmaceuticals Ltd., Besins healthcare (UK) limited., Sichuan Deebio Pharmaceutical Co. Ltd., Changzhou Siyao Pharmaceuticals Co. Ltd., Shanghai Shyndec Pharmaceutical Co. Ltd.

North America was the largest region in the progesterone market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in progesterone report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the progesterone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Progesterone is a steroid hormone that plays a key role in regulating the menstrual cycle, supporting pregnancy, and contributing to embryonic development in humans and other animals. It helps prepare the endometrial lining of the uterus for the implantation of a fertilized egg, supports early stages of pregnancy, and prevents additional ovulation during pregnancy. Additionally, progesterone is utilized in hormone replacement therapy and in contraceptive pills, where it is used in synthetic forms known as progestins.

The primary types of progesterone products include natural and synthetic progesterone. Natural progesterone, also known as bioidentical progesterone, is typically extracted from plant sources such as soybeans and wild yams. These products are available in both generic and branded options and can be delivered through various methods, including oral, injectable, transdermal, and others. Progesterone is used in a wide range of applications, including treatment for menopause, birth control, abnormal uterine bleeding, hyperplastic precursor lesions, and endometrial cancer. Key end-users include hospitals, clinics, research institutions, and other medical facilities.

The progesterone market research report is one of a series of new reports that provides progesterone market statistics, including progesterone industry global market size, regional shares, competitors with an progesterone market share, detailed progesterone market segments, market trends and opportunities, and any further data you may need to thrive in the progesterone industry. The progesterone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The progesterone market consists of sales of oral capsules, vaginal gels, creams, injections, and intrauterine devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.